Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Assets (2016 - 2025)

Fennec Pharmaceuticals filings provide 16 years of Assets readings, the most recent being $70.6 million for Q4 2025.

  • On a quarterly basis, Assets rose 56.97% to $70.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $70.6 million, a 56.97% increase, with the full-year FY2025 number at $70.6 million, up 56.97% from a year prior.
  • Assets hit $70.6 million in Q4 2025 for Fennec Pharmaceuticals, up from $49.3 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $70.6 million in Q4 2025 to a low of $15.6 million in Q2 2022.
  • Median Assets over the past 5 years was $28.0 million (2021), compared with a mean of $36.6 million.
  • Biggest five-year swings in Assets: plummeted 44.63% in 2022 and later skyrocketed 224.95% in 2024.
  • Fennec Pharmaceuticals' Assets stood at $22.4 million in 2021, then increased by 20.19% to $26.9 million in 2022, then dropped by 0.28% to $26.9 million in 2023, then skyrocketed by 67.31% to $44.9 million in 2024, then soared by 56.97% to $70.6 million in 2025.
  • The last three reported values for Assets were $70.6 million (Q4 2025), $49.3 million (Q3 2025), and $44.9 million (Q2 2025) per Business Quant data.